SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH
申请人:Luzzio Michael Joseph
公开号:US20090054395A1
公开(公告)日:2009-02-26
The present invention relates to a compound of the formula I
wherein R
1
to R
6
, A, B, n and m are as defined herein. Such novel sulfonyl amide derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to a method of using such compounds in the treatment of abnormal cell growth in mammals, especially humans, and to pharmaceutical compositions containing such compounds.
[DE] NEUE DERIVATE VON C.I. PIGMENT RED 170<br/>[EN] NOVEL DERIVATIVES OF C.I. PIGMENT RED 170<br/>[FR] NOUVEAUX DERIVES DU C.I. PIGMENT ROUGE 170
申请人:CLARIANT GMBH
公开号:WO2003099936A1
公开(公告)日:2003-12-04
Verbindungen der Formel (1) oder Tautomere davon, worin X die Bedeutung F, Cl, Br, Methyl oder Nitro hat, zeichnen sich durch höhere Gelbstichigkeit, Transparenz und Wetterechtheit gegenüber unsubstituiertem Pigment Red 170 aus.
公式(1)或其互变异构体的化合物中,其中X表示F、Cl、Br、甲基或硝基,这些化合物相对于未取代的Pigment Red 170具有更高的黄色调、透明度和耐候性。
MRNA-BASED GENE EXPRESSION FOR PERSONALIZING PATIENT CANCER THERAPY WITH AN MDM2 ANTAGONIST
申请人:Hoffmann-La Roche Inc.
公开号:US20150211073A1
公开(公告)日:2015-07-30
Use of at least an MDM2 gene panel, preferably a four gene MDM2 gene panel, as a biomarker for predicting the response to a MDM2 antagonist.
There are provided compounds of the formula
wherein X, Y, R
1
, R
2
, R
3
, R
3
, R
4
, R
5
, R
6
and R
7
are as described herein
and enantiomers and pharmaceutically acceptable salts and esters thereof. The compounds are useful as anticancer agents.
A compound represented by formula (1):
wherein X is a single bond or a substituted or unsubstituted lower alkylene group; Z is a saturated or unsaturated monocyclic hydrocarbon ring group or the like; and each of R
1
, R
2
, R
3
and R
4
, which may be the same or different, is a hydrogen atom, a halogen atom, a nitro group, a cyano group, a carboxyl group, a substituted or unsubstituted alkyl group, or the like, a prodrug of said compound, or a pharmaceutically acceptable salt of said compound or prodrug has inhibitory effect on Rho kinase and hence is useful for treating diseases which are such that morbidity due to them is expected to be improved by inhibition of Rho kinase and secondary effects such as inhibition of the Na
+
/H
+
exchange transport system caused by the Rho kinase inhibition, for example, hypertension.